Gerard Craughwell (Independent)

I thank the Minister of State for being in the House today. I think it is the first time I have addressed him since his elevation. I congratulate him. He was a great Senator when he was here and I am sure he is doing equally well as a Minister.

Respiratory syncytial virus, RSV, is a common and highly contagious virus that affects the lungs and respiratory tract. While it can affect people of all ages, older adults, particularly those over 60, face a significantly higher risk of severe illness, hospitalisation and death. Across Ireland and Europe, RSV contributes to tens of thousands of hospitalisations and thousands of deaths annually in this age group. Adults with underlying health conditions such as COPD, asthma, diabetes and heart failure are especially vulnerable.

The rationale for introducing RSV vaccine for older adults is clear, to protect this high-risk population from serious lower respiratory tract infections. Clinical trials of the vaccine, like GSK's trials, have shown strong efficacy of over 80% overall and more than 90% in adults with comorbidity, alongside a favourable safety profile, with mostly mild and temporary side effects. From a cost-benefit perspective, the Health Information and Quality Authority, HIQA, estimates that to vaccinate all adults aged 65 and over would cost approximately €146 million for the 2025-26 season. It is important to say that the vaccine has a three-term span, so that is once every three years. Targeting those aged 75 and over would cost around €76 million. While direct costs offset from reduced hospitalisation are modest, at around €1 million, the broader benefits are substantial. These include fewer severe illnesses, reduced medical complications and improved quality of life. RSV also exacerbates chronic conditions and disrupts daily activities in older adults. Vaccination could ease the burden on the healthcare system and enhance patients’ well-being. International experience supports this, with the early data showing promising reductions in hospital admissions following the vaccine. Specifically, there is research from Scotland which is absolutely astounding in respect of the reduction in hospitalisation as a result of RSV, which we heard about last week in Buswells Hotel.

In conclusion, the introduction of RSV vaccine for Irish adults over 60 is a sound public health measure despite the upfront cost. The vaccine is of strong efficacy and safety and offers potential to prevent serious illness and complications, especially in those with underlying conditions. This makes it a worthwhile investment in protecting Ireland’s ageing population. In the UK, the RSV vaccine is now available for adults between the ages of 70 and 79 or 80; I think you can get it up to one day before your 80th birthday and it is free. I inquired the other day to get the vaccine myself. Having spoken to some people in Buswells, I am totally convinced that it is a worthwhile endeavour. It would cost €235 for me to get the vaccine myself. I am anxious to hear what the Department has given the Minister to say.